Cardinal Health Continues Support of Future Pharmacists with 2015 Scholarship Funding

Shark.tidbits

DUBLIN, Ohio, July 9, 2015 /PRNewswire/ — As part of its continued commitment to supporting future pharmacists, Cardinal Health announced that 10 pharmacy schools across the country will collectively receive more than $1 million in funding through the Cardinal Health Pharmacy Scholarship Program in 2015 exceeding $1 Million. read more

Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of Bexarotene 75mg Capsules, which is the generic version of Valeant’s Targretin® Capsules. This product is indicated for the treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy.(1)  read more

Sorrento and NantBioScience Form Joint Venture to Develop Moonshot Program Targeted Small Molecule Therapies against Cancer   SAN DIEGO, July 9, 2015 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today that they have established a joint venture to focus on the development of ‘first-in-class’ small molecules against targets that have eluded the pharmaceutical industry to date and which may address important drivers of cancer growth including cancer stem cells. read more

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection  

TARRYTOWN, N.Y. and PARIS, July 8, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent® (alirocumab) Injection met its primary endpoint. At week 24, patients in the Praluent group experienced an average 64 percent greater reduction from baseline in their bad cholesterol, known as low-density lipoprotein cholesterol (LDL-C), when added to current standard of care including statins, compared to standard of care alone  read more

Improving Cancer Diagnosis and Treatment Monitoring With GLAM Project

BARCELONA, Spain–(EON: Enhanced Online News)–The project Glass-Laser Multiplexed Biosensor, GLAM for short, will use groundbreaking technology to develop a device that is a step towards truly personalized medicine. The photonic-based point-of-care device will help oncologists make better treatment decisions according to the patient’s needs in a non-invasive manner for cancer diagnosis. read more

Tillotts Pharma AG under Agreement to Acquire Global Rights for Entocort® (budesonide) from AstraZeneca Outside the U.S. Tillotts is under agreement to expand and diversify the company’s portfolio by acquiring Entocort®, an established, locally-acting glucocorticosteroid, indicated for the treatment of inflammatory bowel disease (IBD), from AstraZenecaThis transaction underscores Tillotts’ commitment to become a major European specialist in the field of gastroenterology, offering patients a wide range of treatments for gastrointestinal (GI) disorders while delivering value to shareholders
Tillotts will be acquiring the global rights to Entocort®, excluding the United States (U.S.)

 

 

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.